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Abstract
Bypass of replication blocks by specialized DNA polymerases is crucial for cell survival but may promote mutagenesis and
genome instability. To gain insight into mutagenic sub-pathways that coexist in mammalian cells, we examined N-2-
acetylaminofluorene (AAF)-induced frameshift mutagenesis by means of SV40-based shuttle vectors containing a single
adduct. We found that in mammalian cells, as previously observed in E. coli, modification of the third guanine of two target
sequences, 5’-GGG-3’ (3G) and 5’-GGCGCC-3’ (NarI site), induces –1 and –2 frameshift mutations, respectively. Using an in
vitro assay for translesion synthesis, we investigated the biochemical control of these events. We showed that Pol eta, but
neither Pol iota nor Pol zeta, plays a major role in the frameshift bypass of the AAF adduct located in the 3G sequence. By
complementing PCNA-depleted extracts with either a wild-type or a non-ubiquitinatable form of PCNA, we found that this
Pol eta-mediated pathway requires Rad18 and ubiquitination of PCNA. In contrast, when the AAF adduct is located within
the NarI site, TLS is only partially dependent upon Pol eta and Rad18, unravelling the existence of alternative pathways that
concurrently bypass this lesion.
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Introduction
Translesion synthesis (TLS) is a regulated and coordinated
process in which the replacement of the high fidelity replicative
DNA polymerase by one or several specialized TLS polymerases
allows replication through DNA blocking lesions that have escaped
repair. Human TLS DNA polymerases include Y-family poly-
merases –DNA polymerase eta (Polg), DNA polymerase iota
(Poli), DNA polymerase kappa (Polk), and Rev1- and one B-family
polymerase, DNA polymerase zeta (Polf) that cooperate to deal
with the vast diversity of DNA damages [1]. In humans, loss of Pol
eta, required for accurate replicative bypass of cyclobutane
pyrimidine dimers induced by UV radiation, results in the variant
form of Xeroderma pigmentosum (XPV) [2,3].
The Rad6/Rad18 dependent monoubiquitination of PCNA
(Proliferating Cell Nuclear Antigen), sliding clamp associated to
the DNA polymerases, is critical for TLS regulation [4,5,6,7]. In
addition, eukaryotic TLS polymerases are regulated by post-
translational modifications [8,9,10,11] that may modulate their
interactions with specific protein partners.
It is clear that different sub-pathways of TLS coexist in
eukaryotic cells due to the large variety of lesions and proteins
involved. The characterization of proteins required for TLS across
a given lesion is a useful approach to precisely understand their
regulation. In this paper, we analysed the bypass of the N2-acetyl-
aminofluorene (AAF) adduct in mammalian cells. Binding of the
AAF on the C8 of guanine residues severely impairs DNA
replication by high-fidelity replicative DNA polymerases [12].
DNA synthesis opposite AAF lesions has been shown to involve
a combination of specialized DNA polymerases in E. coli [13] and
S. cerevisiae [14,15,16]. In addition in E. coli, AAF adducts trigger
hot spots (i) of –1 frameshift mutations when located at the third G
in monotonous runs of G bases (5’-GGG-3’ 5’-GG-3’) and (ii) of –
2 frameshift mutations in regions of alternating GC base pairs,
further referred to as the NarI site (5’-GGCGCC-3’ 5’-GGCC-3’)
[17]. Within these two particular DNA sequence contexts,
insertion of a cytosine residue opposite the lesion increases the
likelihood of forming slipped mispairs that, when elongated, give
rise to frameshift products. Despite similar slippage mechanisms,
the AAF bypass within these two DNA sequences requires
a different set of DNA polymerases in E. coli [13]. In this paper,
we present data showing that –1 and –2 frameshift mutations are
observed in mammalian cells transfected with SV40-based shuttle
vectors monomodified on the third guanine of each target DNA
sequence. Using cell-free extracts, we examined the contribution
of different translesional DNA polymerases to the bypass within
these two sequence contexts. We clearly show that whereas Pol eta,
along with Rad18 and monoubiquitinated PCNA, fully mediate
the bypass of the AAF adduct located within the 3G sequence,
these proteins only partially contribute to the bypass across the
same lesion within the NarI site, thus unravelling a yet
uncharacterized Rad18-independent TLS pathway.
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Cell lines and culture conditions
Cells were grown at 37uC in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% foetal calf serum and
1% gentamicin (0.5 mg/ml). MRC5-V1 cells are SV40-trans-
formed normal human lung fibroblasts [18]. COS-7 cells are
African green monkey SV40-transformed kidney fibroblasts [19].
The XP30RO cell line (SV40-transformed XPV human fibro-
blasts) has a homozygous deletion in the Pol eta gene resulting in
a truncated protein of only 42 amino acids [3]. XP12RO cells
(SV40-transformed XPA human fibroblasts) were cultured in the
presence of hygromycin (250 mg/ml) for the maintenance of the
plasmid p205-KMT11 encoding the SV40 T antigen [20]. The
type I Burkitt’s lymphoma BL2 cell lines, in which the genes
coding for Rev3, Pol eta, Pol iota or for both Pol eta and Pol iota
have been inactivated by homologous recombination, were
already described [21]. The human colon carcinoma cell line
HCT116-Rad18
KO [22] was cultured in the presence of G418
(300 mg/ml) and puromycin (0.3 mg/ml).
Construction of the monomodified plasmids
The construction of the AAF monomodified single-stranded
plasmids (pUC3G and pUCNar) and the SV40 origin-containing
vectors have been described previously [23,24,25]. The single AAF
adduct is located either on the leading or the lagging strand
templates in the early part of the lacZ gene in a +1 (for the
pMKB3G and the pMZB3G) or +2 (for the pMKBNar and
pMZBNar) reading frame, allowing respectively for –1 or –2
frameshift errors to be detected phenotypically in E. coli as blue
colonies on Xgal-containing indicator plates.
Transfection and rescue of the replicated plasmids
COS-7 cells were seeded at a density of 5610
5 per 100 mm
dish, incubated for 24 hours and transfected with plasmid DNA by
the calcium phosphate coprecipitation method. Transfection was
performed with 50 ng of the AAF-monomodified plasmid shuttle
vector and 5 mg carrier plasmid DNA (pBR329). Cells were
incubated for 48 hours and then collected for extrachromosomal
DNA extraction by the HIRT procedure [26]. At least three
independent cell transfections were performed for each plasmid.
Bacterial transformation and mutant characterization
Plasmid DNA isolated from transfected cells was digested with
DpnI to restrict all input plasmid DNA that retained the
bacterial methylation pattern and could give rise to white
colonies. E. coli strains TB1 were transformed by the DpnI-
digested plasmids, and transformants were analysed on indicator
plates containing 100 mg/ml of X-Gal (5-bromo-4-chloro-3-
indolyl b-D-pyranoside) (Roche), 1 mM IPTG (isopropyl b-D-
thiogalactopyranoside) (Roche) and 50 mg/ml ampicillin (Sigma).
Mutagenesis was detected by means of a colorimetric assay
(white to blue) based on a,w-complementation of beta-galacto-
sidase, as the target sequence is located on the lacZ’ gene of the
shuttle vector. Blue mutant colonies were purified by retransfor-
mation into TB1. Plasmid DNA from purified blue colonies was
recovered by the alkaline lysis method and sequenced. The
frequency of –1 or –2 frameshift mutagenesis at the 3G sequence
or at the NarI site was calculated as the ratio of –1 or –2
targeted mutant colonies to total transformants, respectively.
Primer extension analysis
Primer extension analysis were performed in the conditions
previously described [27]. The reaction mixture (6.25 ml)
containing 10 fmoles of primed circular single-stranded DNA
and the whole cell extract (10–30 mg) was incubated at 37uC for
30 min to 1 hour in 50 mM Hepes-KOH (pH 7.9), 7 mM
MgCl2, 1 mM DTT, 4 mM ATP, 200 mM of dNTPs, 40 mM
creatine phosphate, 100 mg/ml creatine kinase. Replication
products were digested with EcoRI and PvuII restriction
enzymes and analysed by electrophoresis on a 8% polyacryl-
amide-7 M urea denaturing gel. Quantification of the levels of
TLS was determined by Phospho-Imager and Image J analysis.
The percentage of TLS was calculated as the ratio of the
intensity of the bands of non-slipped TLS (TLS 0) or slipped
TLS (TLS –1 or –2) to the sum of the intensity of the TLS, L-1
and L0 bands.
Preparation of PCNA-depleted extracts
For the depletion of PCNA from cell extracts, we took
advantage of the PCNA binding capacities of a previously
described peptide, P21 consensus motif 1 (CON1: SAVLQK-
KITDYFHPKK) [28]. 5’ phosphorylated complementary oligos
encompassing the DNA sequence coding for this peptide (5’-
catggctAGCGCGGTGCTGCAGAAAAAAATTACCGAT-
TATTTTCATCCGAAAAAATAATAAggtac-3’ and 5’-cTTAT-
TATTTTTTCGGATGAAAATAATCGG-
TAATTTTTTTCTGCAGCACCGCGCTagc-3’; Sigma-
Aldrich) were annealed and ligated to NcoI – KpnI digested
pETM-30 scaffold (Invitrogen) to generate the pET-CON1 vector
expressing a 6His-GST-CON1 peptide fusion. The peptide was
over-expressed in BL21 E. coli cells and further purified by metal
chelate affinity chromatography using a BioLogic system (Biorad)
and HisTrap HP column (GE Healthcare). The purified fusion
Table 1. Mutagenic TLS through AAF within the 3G sequence or the NarI site in COS-7 and XP12RO cells.
Plasmids Nar0 Nar3.AAF Nar3.AAF 3G0 3G3.AAF 3G3.AAF
AAF location 2 Leading Lagging 2 Leading Lagging
Frameshift mutation frequency
(10
25) in COS-7 cells
,22 1 3 1 ,1 737 1099
Number of colonies in COS-7 cells 0/45,218 12/56,921 20/63,820 0/72,912 485/65,797 487/44,287
Frameshift mutation frequency
(10
25) in XP12RO cells
,91 7 2 4 ,1 1345 1303
Number of colonies in XP12RO
cells
0/10,884 3/17,460 5/20,925 0/98,976 383/28,471 360/27,620
Frequencies of frameshift mutations were expressed as the ratio of the targeted mutant blue colonies to total transformants.
doi:10.1371/journal.pone.0036004.t001
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magnetic beads (Invitrogen) according to the manufacturer’s
instructions (500 mg of peptide per 3 mg of beads). After extensive
washes, the beads were mixed with 5 mg of cellular extracts in
850 ml of DIA buffer (100 mM potassium glutamate, 30 mM
HEPES pH 7.9, 1 mM DTT, 10% glycerol) containing 50 mM
NaCl and incubated for 1 hour at 4uC with continuous rotation.
After magnetic separation, the supernatant was filtered through
Ultrafree MC 0.45 mm HV Durapore filters (Millipore). The
efficiency of the depletion was checked by Western blotting.
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Figure 1. TLS through the G-AAF adduct in the Pol h, Pol i and Rev3 mutant BL2 cell-free extracts. Diagram of the AAF-modified
plasmids (panel A). Lengths of the strands produced upon elongation of the labeled primer are indicated; nt, nucleotides. 10 fmoles of unmodified
DNA (panel B) or AAF-modified substrates (panels C and D) were incubated 30 min at 37uC in the presence of BL2 cell-free extracts (15 mg) in a final
volume of 6.25 ml, as indicated. The samples were analysed by electrophoresis through a 8% denaturing polyacrylamide gel. L-1 and L0 are products
generated if synthesis is blocked one nucleotide before and opposite the lesion, respectively. TLS0 and TLS-1 or –2 are products from TLS via non-
slipped and slipped intermediates, respectively. Models for the bypass of the AAF lesion in the two sequence contexts are shown below each gel. The
length of each arrow is proportional to the involvement of the different factors.
doi:10.1371/journal.pone.0036004.g001
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AAF-induced frameshift mutagenesis in mammalian cells
We designed two families of shuttle vectors containing a site-
specific AAF adduct on the third G in either a run of three
guanines (5’-GGG
AAF-3’, referred to as 3G3.AAF) or an
alternating GC sequence (5’-GGCG
AAFCC-3’, referred to as
Nar3.AAF) located within the lacZ’ target gene. The SV40 origin-
containing plasmids were transfected in COS-7 cells, and after
48 hours incubation of the cells, the plasmid DNA was isolated
and transformed into E. coli in order to phenotypically detect
frameshift mutations.
In COS-7 cells transfected with the unmodified plasmids, the
spontaneous mutation frequency is less than 10
25 (Table 1). AAF
modification at the third G increases the –2 frameshift mutation
frequency at the NarI site to about 2610
24, and the –1 frameshift
mutation frequency at the three G run to about 10
22 (Table 1).
We did not observe any blue mutant colony upon transfection of
vectors modified on the first or the second G of the NarI sequence
(among 80,409 transformants for Nar1.AAF and 191,128
transformants for Nar2.AAF; data not shown), demonstrating that
only the presence of the adduct at the third G is critical to induce
frameshift mutagenesis. The relatively low frequency of –2
frameshift mutagenesis compared to the –1 frameshift mutagenesis
was also found upon transfection in the repair-deficient human cell
line XP12RO (XPA; Table 1), showing that the higher
mutagenicity of the AAF adduct located at the 3G sequence does
not result from a preferential repair of the Nar3.AAF substrate. It
should be stressed that the overall contribution of TLS to the AAF
bypass in mammalian cells is potentially much higher as only
frameshift TLS events are scored in this assay. In both sequence
contexts, the AAF-induced mutation frequency is not significantly
different whether the adduct is located on the leading or the
lagging strand (Table 1). This result is consistent with similar
studies that monitor TLS through CPD lesions [29], 6–4
photoproducts [30], or a thymine glycol [31] in human cells using
equivalent assays. Collectively, these observations suggest that
similar genetic mechanisms contribute to TLS, irrespective of the
location of the lesion on the leading or the lagging DNA strand of
an episomal plasmid.
In E. coli, it has been shown that a different set of DNA
polymerases is involved in the bypass of the AAF adduct located
within the two different sequence contexts analysed here, Pol II (a
B-family DNA polymerase) being exclusively required for –2
frameshift mutagenesis, whereas Pol V (a Y-family DNA poly-
merase) is involved in –1 frameshift mutagenesis [13]. In contrast
in S. cerevisae, the frameshift mutagenesis induced by AAF adducts
within both repetitive sequences depends on Pol zeta [15]. These
differences between organisms and the high –1 mutation
frequency obtained in mammalian cells compared to the –2
mutation frequency prompted us to further investigate the
biochemical control of these two pathways.
Evidence for a Pol eta-independent TLS pathway
We have previously shown that extracts from wild-type primary
or transformed cells were able to perform TLS through an AAF
adduct located at the 3G sequence 10-fold more efficiently than
extracts from XPV cells, indicating that DNA Pol eta is involved in
the reaction [27,32]. In order to evaluate the role of this DNA
polymerase and of possible other TLS polymerases (in particular
the B-family polymerase Pol zeta) in the bypass of AAF adducts
within the two sequence contexts analysed in this paper, we
conducted similar experiments with extracts from BL2 cells
knocked-out for Pol eta and Pol iota (either singly or in
combination), and for REV3L (the catalytic subunit of Pol zeta)
[21]. We measured the capacity of the cell-free extracts to extend
a primer past an AAF adduct located at the third G in the 3G or
NarI sequences on a circular single-stranded DNA plasmid
(Fig. 1A). This approach allowed us to analyse the partitioning
between non-slipped (TLS0) and slipped products (TLS-1 or TLS-
2).
As shown in figure 1B, the different extracts display identical
DNA synthesis activities when tested with a primed unmodified
single-stranded template. In the presence of an AAF adduct, the
patterns of the elongation products indicate that extracts from
wild-type cells are able to bypass the AAF lesion efficiently in
either sequence context. When the AAF adduct is located in the
-L-1
-TLS 0
-TLS-2
-TLS 0
-L-1
-TLS-1
pUC3G3.AAF pUCNar3.AAF
MRC5
X30RO
MRC5
XP30RO
 TLS 0     28       12     % TLS 0 13      10   %
40       0    % TLS-1     20       16     % TLS-2
Figure 2. TLS through the G-AAF adduct in MRC5 and XP30RO
cell-free extracts. MRC5 (WT) and XP30RO (Pol eta deficient) cell-free
extracts (20 mg) were incubated 30 min at 37uC in the presence of
10 fmoles of AAF-modified substrates either at the 3G sequence or at
the NarI site in a final volume of 6.25 ml, as indicated. The samples were
analysed by electrophoresis through a 8% denaturing polyacrylamide
gel. L-1 is a product generated if synthesis is blocked one nucleotide
before the lesion. TLS0 and TLS-1 or –2 are products from TLS via non-
slipped and slipped intermediates, respectively.
doi:10.1371/journal.pone.0036004.g002
pUC3G3.AAF pUCNar3.AAF
    WT     WT Rad18-/- Rad18-/-
L-1- L-1-
TLS0-
TLS-1-
TLS0-
TLS-2-
Extract N°:  1        2          1       2                                 1        2          1         2    
10     10        7      7     % TLS0 15     24        9      13     % TLS0
29     23       9      9     % TLS-1 38     31       51     30     % TLS-2
Figure 3. Analysis of Rad18 dependence of the G-AAF bypass
in HCT116 cell-free extracts. HCT116 cell-free extracts, wild-type
(WT) and Rad182/2 (20 mg), were incubated 30 min at 37uC in the
presence of 10 fmoles of AAF-modified substrates either at the 3G
sequence or at the NarI site in a final volume of 6.25 ml, as indicated.
The samples were analysed by electrophoresis through a 8% de-
naturing polyacrylamide gel. L-1 is a product generated if synthesis is
blocked one nucleotide before and opposite the lesion, respectively.
TLS0 and TLS-1 or –2 are products from TLS via non-slipped and slipped
intermediates, respectively.Quantitative analysis of experiments with
two independent extracts are presented.
doi:10.1371/journal.pone.0036004.g003
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(TLS-1) catalysed by extracts from wild-type cells largely
predominates over the non-slipped elongation reaction (TLS0).
TLS0 is slightly reduced and TLS-1 totally abolished in the
absence of Pol eta, as observed for extracts from primary human
fibroblasts [27,33]. No marked difference was detected between
normal cell extracts and those that contain neither Pol iota nor
Rev3, demonstrating that these two specialized DNA polymerases
do not play any significant role in vitro in TLS through the AAF
adduct in this sequence context. We are aware that we cannot
totally exclude any participation of Rev3 in the bypass, as we have
not checked the TLS activity in the double mutant cell extract, Pol
eta/ Rev3.
When the AAF adduct is located within the NarI sequence,
similar quantities of full length elongation products (TLS0) and
two bases slippage products (TLS-2) were observed upon
incubation with extracts from wild-type cells (Fig. 1D). The
amount of both TLS0 and TLS-2 decreased in Pol eta deficient
extracts, demonstrating that Pol eta is involved in the synthesis of
both products. A significant amount of residual TLS was observed
in extracts from the single Pol eta mutant cells as well as in the
double Pol eta/ Pol iota mutant cells, strongly suggesting the
involvement of at least another DNA polymerase able to perform
both types of TLS through the AAF adduct in the NarI context.
Deletion of the rev3 coding sequence did not significantly change
the amount of the TLS products, indicating that Pol zeta does not
play a major role in the bypass of the AAF lesion in the NarI
sequence, as in the 3G sequence.
To rule out the possibility that these observations are specific to
the lymphoma cell type used, we extended our experiments by
comparing the TLS activities of extracts from either normal
(MRC5) or XPV (XP30RO:Pol eta deficient) transformed human
fibroblasts. The data clearly show that also in fibroblastic cell lines,
the defect in Pol eta results in the absence of TLS-1 on the
pUC3G3.AAF substrate and a strong reduction of both TLS0 and
TLS-2 on the pUCNar3.AAF substrate (Fig. 2).
Altogether, the data presented here show that in human cell
extracts Pol eta, but not Pol zeta, plays a major role in the bypass
of AAF adducts located within the two sequence contexts
analyzed. In S. cerevisiae, this lesion is bypassed in a two-polymerase
mechanism, Pol eta being involved at the insertion step whereas
Pol zeta is required at the extension step [15,16]. Differences in the
biochemical properties of the human as compared to the yeast Pol
eta may account for this divergence. Indeed, although both
enzymes are efficient in incorporating a C opposite the G-AAF
adduct, only the human Pol eta can continue the chain elongation
[34,35].
These results show that distinct pathways coexist in human cells
to bypass the AAF adduct. One of these pathways involves Pol eta,
which is required for all –1 frameshift mutagenesis events at the
3G sequence, and for a significant proportion of both TLS0 and
TLS-2 frameshift mutagenesis at the NarI sequence. In addition,
at least another, yet uncharacterized pathway (X-dependent) is
responsible for some part of the TLS0 at the 3G sequence and for
a sizable fraction of both TLS0 and TLS-2 at the NarI site.
Deciphering this(ese) alternative pathway(s), which also exist in
extracts from primary or transformed XPV fibroblasts (data not
shown), may be of major importance in order to get a better
understanding of mutagenesis in human cells.
Evidence for a Rad18, Ub-PCNA-independent TLS
pathway
Using cell-free extracts, we have previously established that
PCNA is mono-ubiquitinated in a Rad18-dependent manner
during a primer extension reaction when the replication complex
encounters a pausing site on a single-stranded DNA template [32].
Furthermore, TLS through an AAF adduct located on the first G
of the 3G sequence was found to be dependent upon Rad18 [36].
Similarly, we show here that in Rad18 knock-out cell extracts, the
efficiency of TLS-1, which exclusively depends on Pol eta activity
is drastically reduced as compared to that of wild-type cell extracts
(Fig. 3). Surprisingly, when we used the pUC.Nar3AAF substrate
in the same assay, the depletion of Rad18 resulted in a decrease in
TLS0 without affecting TLS-2 (Fig. 3), indicating that Rad18 by
itself or Ub-PCNA (or both) are not absolutely required for the
production of TLS-2 at the NarI site, thus uncovering a Rad18-
independent frameshift mutagenesis pathway in mammalian cells.
It has to be noted that upon incubation with pUCNar3.AAF, the
HCT116 cell extract shows a slightly higher TLS-2 efficiency than
BL2 (Fig. 1) and MRC5 (Fig. 2) cell extracts. These data suggest
B
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Figure 4. Analysis of Ub-PCNA dependence of G-AAF bypass in
MRC5 cell-free extracts. Mock depleted (M) or PCNA depleted MRC5
cell extracts (20 mg) were incubated 30 min at 37uC in the presence of
10 fmoles of unmodified or modified substrates in a final volume of
6.25 ml, as indicated. Recombinant wild-type (WT) or mutated K164R
PCNA (60 ng) was added to the reactions, as indicated. Aliquotes of the
samples were analysed either by Western blot with an anti-PCNA
antibody (panel A) or by 8% denaturing polyacrylamide gel electro-
phoresis (panel B). L-1 is a product generated if synthesis is blocked one
nucleotide before the lesion. TLS0 and TLS-1 or –2 are products from
TLS via non-slipped and slipped intermediates, respectively. FL are Full
Length products.
doi:10.1371/journal.pone.0036004.g004
Rad18-Independent Frameshift Mutagenesis Pathway
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e36004that distinct cell types may express different amounts of factors
involved in each specific pathway.
Whether Rad18 contributes to TLS in cell-free extracts by
interacting with Pol eta or by triggering PCNA ubiquitination
remains uncertain. In order to examine more directly the role of
Ub-PCNA in the bypass of the AAF adduct, we performed the
elongation reactions in a cell extract, first depleted for PCNA and
then complemented with either wild-type or K164R mutated
PCNA. We exploited the very strong and specific interaction
between PCNA and a peptide derived from p21 [28] to deplete
PCNA nearly to completion in MRC5 cell-free extracts (Fig. 4A).
As expected, endogenous PCNA and purified wild-type PCNA,
but not K164R PCNA, were monoubiquitinated during the
primer extension reaction (Fig. 4A). Both wild-type and K164R
purified PCNA were able to restore efficient primer extension on
an unmodified substrate, indicating that essential proteins have not
been co-depleted together with PCNA (Fig. 4B). Both wild-type
and K164R PCNA were equally able to rescue the bypass of the
CPD lesion (Fig. 4B), demonstrating unambiguously that the
ubiquitylation-defective PCNA mutant is a functionally proficient
sliding clamp able to promote TLS through this UV-induced
lesion, consistent with another in vitro study [37]. This result is in
agreement with a model in which Pol eta can be recruited at the
site of the damage in the absence of Ub-PCNA in human
fibroblasts [38]. We have previously shown [36] that the PCNA
interacting peptide (PIP) motif of Pol eta is required for efficient
bypass of CPD in this system. Hence, interaction of Pol eta with
PCNA, and possibly with other proteins, is sufficient to stabilize
the TLS polymerase during CPD bypass. Recently TLS across
a TT CPD has been shown to occur in mouse embryo fibroblasts
expressing PCNA K164R [39], albeit at reduced extent than in
cells expressing wild type PCNA. Furthermore, Pol eta provides
a critical advantage for UV survival and replication blocks
recovery in mouse embryo fibroblasts expressing PCNA K164R
[39,40]. Collectively, these in vivo data show that Pol eta activation
may occur independently of Ub-PCNA.
On the contrary, K164R PCNA is not able to promote TLS
through the AAF adduct located at the 3G sequence (Fig. 4B),
pointing to the importance of the posttranslational modification of
PCNA at this site for the bypass of the AAF adduct by Pol eta,
presumably by increasing its residence time [38].
Unexpectedly, when the AAF adduct was located in the NarI
site, the ubiquitylation-defective mutant K164R PCNA partially
rescued TLS0, and even more TLS-2. Hence, in this sequence
context, an as yet uncharacterized pathway is able to generate
TLS0 and TLS-2 products in a Rad18 and Ub-PCNA in-
dependent manner.
Conclusions and perspectives
In this paper, we show that in mammalian cells, the protein
requirement for the bypass of an AAF adduct within two different
sequence contexts fundamentally differ.
TLS through the AAF adduct in the 3G sequence is mediated
by DNA polymerase eta and requires Rad18 and Ub-PCNA. The
high proportion of slipped TLS observed in vitro presumably
accounts for the high frequency of –1 frameshift mutagenesis
observed in vivo upon transfection of mamalian cells with the 3G3
monomodified plasmid. In comparison, the frequency of –2
frameshift observed upon transfection with the Nar3 monomodi-
fied plasmid is low and does not correlate with the amount of TLS-
2 observed in vitro. In vivo, the bypass of a DNA damage triggers
many different responses among which TLS is only one of them.
Damage avoidance pathways that are not active in our in vitro
assay may contribute more efficiently in vivo, to the bypass of the
AAF lesion within the NarI sequence than within the 3G
sequence. Given the specific signature of Pol eta, relative to the
AAF-induced mutations within the 3G sequence, the correspond-
ing AAF monomodified plasmid provides a useful tool to
investigate the regulation of this DNA polymerase in human cells
and to examine the impact of different mutations in the protein.
Bypass of the AAF adduct was achieved in non-irradiated cells,
indicating that ubiquitination of PCNA and recruitment of Pol eta
does not depend on global checkpoint activation, but on cis-acting
factors at the blocked replication fork. In addition to the Pol eta
and Ub-PCNA dependent pathway, the bypass of the AAF adduct
positioned within the NarI site is partially dependent upon
another, as yet uncharacterized pathway that does not involve
Rad18. One important goal will be to identify the DNA
polymerase(s) involved in this pathway and to elucidate its
regulation.
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